|
22 Sep 2025 |
Alembic Pharma
|
Consensus Share Price Target
|
950.70 |
1056.64 |
- |
11.14 |
buy
|
|
|
|
|
29 Oct 2015
|
Alembic Pharma
|
Karvy
|
950.70
|
650.00
|
679.90
(39.83%)
|
Target met |
Sell
|
|
|
In Q2FY16, total revenues of Alembic Pharmaceuticals increased by 84.4% YoY to Rs 10.1 bn (our estimates Rs 10.8 bn) compared to Rs 5.5 bn in Q2FY15, due to higher export formulations sales on account of revenues generated from Abilify opportunity.
|
|
03 Aug 2015
|
Alembic Pharma
|
Karvy
|
950.70
|
716.00
|
736.65
(29.06%)
|
Target met |
Sell
|
|
|
In Q1FY16, total revenues of Alembic Pharmaceuticals increased by 18% YoY to Rs 5.8 bn (our estimates Rs 5.5 bn) compared to Rs 4.9 bn in Q1FY15, due to higher export formulations sales. The Company's operating margins decreased by 210bps to 17.5% on back of lower gross margins and higher R&D cost.
|
|
28 Apr 2015
|
Alembic Pharma
|
Karvy
|
950.70
|
446.00
|
451.25
(110.68%)
|
Target met |
Sell
|
|
|
In Q4FY15, total revenues of Alembic Pharmaceuticals increased by 8.4% YoY to Rs5.03 bn (our estimates Rs5.06 bn) compared to Rs4.64 bn in Q4FY14, due to higher domestic formulations sales. The Company's operating margins were at similar levels at 19.7% on back of higher other expenses which offset higher gross margins.
|